The multiple sclerosis relapse experience: Patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Nickerson, Molly ^a   Marrie, Ruth A ^b  

^a Questcor Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Corticosteroids; Methylprednisolone; Multiple sclerosis; Prednisone; Relapses

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PLASMAPHERESIS; REGISTER; RELAPSE; RETROSPECTIVE STUDY;

CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION ROUTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MULTIPLE SCLEROSIS; NORTH AMERICA; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 84883631229     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-119     Document Type: Article

References (29)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000, 343:938-952. 10.1056/NEJM200009283431307, 11006371.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517. 10.1016/S0140-6736(08)61620-7, 18970977.
3. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003, 61:1528-1532. 10.1212/01.WNL.0000096175.39831.21, 14663037.
4. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008, 255:280-287. 10.1007/s00415-008-0743-8, 18204919.
5. Kalb R. The emotional and psychological impact of multiple sclerosis relapses. J Neurol Sci 2007, 256(Suppl 1):S29-S33.
6. Halper J. The psychosocial effect of multiple sclerosis: the impact of relapses. J Neurol Sci 2007, 256(Suppl 1):S34-S38.
7. Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse: the patient's rerspective. Patient 2012, 5:57-69. 10.2165/11592160-000000000-00000, 22217263.
8. National Clinical Advisory Board of the National Multiple Sclerosis Society Recommendations regarding corticosteroids in the management of multiple sclerosis 2008, New York: National Multiple Sclerosis Society, National Clinical Advisory Board of the National Multiple Sclerosis Society.
9. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000, 4:CD001331.
10. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology 2000, 55:51-54. 10.1212/WNL.55.1.51, 10891905.
11. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009, 72:1760-1765. 10.1212/WNL.0b013e3181a609f8, 2683738, 19451531.
12. van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Mult Scler 2010, 16:604-610. 10.1177/1352458509359922, 20086019.
13. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler 2007, 13:770-775. 10.1177/1352458506075031, 17525097.
14. Vollmer TL, Ni W, Stanton S, Hadjimichael O. The NARCOMS patient registry: a resource for investigators. Int J MS Care 1999, 1:28-34.
15. Consortium of Multiple Sclerosis Centers North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. http://narcoms.org/, Consortium of Multiple Sclerosis Centers.
16. Davis P, Tyry T. NARCOMS Report - 2007 Registry Update. http://www.unitedspinal.org/msscene/2008/02/04/narcoms-report-2007-registry-update.
17. Repovic P, Lublin FD. Treatment of multiple sclerosis exacerbations. Neurol Clin 2011, 29:389-400. 10.1016/j.ncl.2010.12.012, 21439448.
18. Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009, 3:CD006921.
19. Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 2002, 105:164-168.
20. Ozakbas S, Cagiran I, Ormeci B, Idiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 2004, 218:3-7. 10.1016/j.jns.2003.09.015, 14759626.
21. Pascual AM, Bosca I, Coret F, Escutia M, Bernat A, Casanova B. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale. Eur J Neurol 2008, 15:284-288. 10.1111/j.1468-1331.2008.02061.x, 18290849.
22. Giordano A, Pucci E, Naldi P, Mendozzi L, Milanese C, Tronci F, Leone M, Mascoli N, La ML, Giuliani G, Solari A. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study. J Neurol Neurosurg Psychiatry 2009, 80:1023-1028. 10.1136/jnnp.2008.171181, 19443471.
23. Hoogervorst EL, Kalkers NF, van Winsen LML, Uitdehaag BM, Polman CH. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis. Mult Scler 2001, 7:335-339.
24. Iuliano G, Napoletano R, Esposito A. Multiple sclerosis: relapses and timing of remissions. Eur Neurol 2008, 59:44-48. 10.1159/000109260, 17917457.
25. Healy BC, Degano IR, Schreck A, Rintell D, Weiner H, Chitnis T, Glanz BI. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res 2012, 21:1677-1684. 10.1007/s11136-011-0108-0, 22237991.
26. Myhr KM, Mellgren SI. Corticosteroids in the treatment of multiple sclerosis. Acta Neurol Scand Suppl 2009, 189:73-80.
27. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol 2010, 225:9-17. 10.1016/j.expneurol.2009.11.019, 19961850.
28. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285. 10.1056/NEJM199801293380502, 9445407.
29. Rieckmann P. Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int MS J 2005, 12:42-51.